Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery

Ipilimumab, a human monoclonal antibody against cytotoxic T-lymphocyte antigen 4, was approved by the U.S. FDA (Food and Drug Administration) in 2011 for the treatment of unresectable or metastatic malignant melanoma. Occurrence of hypophysitis, an immune-related adverse event due to ipilimumab use,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Fumine, Kogue, Ryota, Maeda, Masayuki, Umino, Maki, Nakai, Yasuo, Takeshita, Atsuro, Sakuma, Hajime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Neuroradiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826684/
https://www.ncbi.nlm.nih.gov/pubmed/29487665
http://dx.doi.org/10.1016/j.radcr.2017.11.007
_version_ 1783302382212349952
author Tanaka, Fumine
Kogue, Ryota
Maeda, Masayuki
Umino, Maki
Nakai, Yasuo
Takeshita, Atsuro
Sakuma, Hajime
author_facet Tanaka, Fumine
Kogue, Ryota
Maeda, Masayuki
Umino, Maki
Nakai, Yasuo
Takeshita, Atsuro
Sakuma, Hajime
author_sort Tanaka, Fumine
collection PubMed
description Ipilimumab, a human monoclonal antibody against cytotoxic T-lymphocyte antigen 4, was approved by the U.S. FDA (Food and Drug Administration) in 2011 for the treatment of unresectable or metastatic malignant melanoma. Occurrence of hypophysitis, an immune-related adverse event due to ipilimumab use, has been frequently reported. We report a case of ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum, identified using 3D fluid-attenuated inversion recovery.
format Online
Article
Text
id pubmed-5826684
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-58266842018-02-27 Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery Tanaka, Fumine Kogue, Ryota Maeda, Masayuki Umino, Maki Nakai, Yasuo Takeshita, Atsuro Sakuma, Hajime Radiol Case Rep Neuroradiology Ipilimumab, a human monoclonal antibody against cytotoxic T-lymphocyte antigen 4, was approved by the U.S. FDA (Food and Drug Administration) in 2011 for the treatment of unresectable or metastatic malignant melanoma. Occurrence of hypophysitis, an immune-related adverse event due to ipilimumab use, has been frequently reported. We report a case of ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum, identified using 3D fluid-attenuated inversion recovery. Elsevier 2017-12-12 /pmc/articles/PMC5826684/ /pubmed/29487665 http://dx.doi.org/10.1016/j.radcr.2017.11.007 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Neuroradiology
Tanaka, Fumine
Kogue, Ryota
Maeda, Masayuki
Umino, Maki
Nakai, Yasuo
Takeshita, Atsuro
Sakuma, Hajime
Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery
title Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery
title_full Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery
title_fullStr Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery
title_full_unstemmed Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery
title_short Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery
title_sort ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3d fluid-attenuated inversion recovery
topic Neuroradiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826684/
https://www.ncbi.nlm.nih.gov/pubmed/29487665
http://dx.doi.org/10.1016/j.radcr.2017.11.007
work_keys_str_mv AT tanakafumine ipilimumabinducedhypophysitisinvolvingtheoptictractsandtubercinereumevaluatedusing3dfluidattenuatedinversionrecovery
AT kogueryota ipilimumabinducedhypophysitisinvolvingtheoptictractsandtubercinereumevaluatedusing3dfluidattenuatedinversionrecovery
AT maedamasayuki ipilimumabinducedhypophysitisinvolvingtheoptictractsandtubercinereumevaluatedusing3dfluidattenuatedinversionrecovery
AT uminomaki ipilimumabinducedhypophysitisinvolvingtheoptictractsandtubercinereumevaluatedusing3dfluidattenuatedinversionrecovery
AT nakaiyasuo ipilimumabinducedhypophysitisinvolvingtheoptictractsandtubercinereumevaluatedusing3dfluidattenuatedinversionrecovery
AT takeshitaatsuro ipilimumabinducedhypophysitisinvolvingtheoptictractsandtubercinereumevaluatedusing3dfluidattenuatedinversionrecovery
AT sakumahajime ipilimumabinducedhypophysitisinvolvingtheoptictractsandtubercinereumevaluatedusing3dfluidattenuatedinversionrecovery

Ejemplares similares